Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up.

IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Eran Zittan, Matthew Levy, Shiraz Vered, A Hillary Steinhart, Raquel Milgrom, Mark S Silverberg, Shira Zelber-Sagi
{"title":"Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up.","authors":"Eran Zittan, Matthew Levy, Shiraz Vered, A Hillary Steinhart, Raquel Milgrom, Mark S Silverberg, Shira Zelber-Sagi","doi":"10.1093/ibd/izaf142","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>The Toronto IBD Global Endoscopic Reporting (TIGER) score is a single endoscopic scoring index for both patients with Crohn's disease (CD) and ulcerative colitis (UC). The goal of this study was to assess the direct relationship between TIGER scores and fecal calprotectin (FC) and C-reactive protein (CRP) after 12 months.</p><p><strong>Methods: </strong>A prospective 12-month study conducted in 1 tertiary IBD center. Baseline colonoscopy was performed. Moderate-to-severe mucosal involvement was defined as a TIGER score ≥ 100, Simple Endoscopic Score for Crohn's disease ≥ 6, Mayo Endoscopic Score > 1. FC and CRP levels were documented at each visit. Baseline TIGER, SES-CD, and MES were utilized as a predictor for FC and CRP levels after 12 months.</p><p><strong>Results: </strong>The study population included 107 adults, 52 with CD and 55 with UC. A baseline TIGER score ≥ 100 had a sensitivity and specificity of 0.964 and 0.941, respectively, at predicting a patient having an FC level ≥ 800 μg/g and/or a CRP level ≥ 1.0 mg/dL at 12-month follow-up. A baseline TIGER score ≥ 100 was associated with increased likelihood of having FC > 100 μg/g (P < .001), and ≥ 800 μg/g (P < .001) after 12 months, despite receiving advanced therapy, after the 12-month follow-up period. Similar trends were observed with the SES-CD and MES.</p><p><strong>Conclusions: </strong>The TIGER score is a simple endoscopic score that can be used for both CD and UC that has been shown to have both construct validity with inflammatory marker and noninferiority to the current best-referenced endoscopic scores over a 12-month follow-up period. Future studies should begin incorporating TIGER as a measure of clinical response to interventions and therapeutics.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izaf142","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: The Toronto IBD Global Endoscopic Reporting (TIGER) score is a single endoscopic scoring index for both patients with Crohn's disease (CD) and ulcerative colitis (UC). The goal of this study was to assess the direct relationship between TIGER scores and fecal calprotectin (FC) and C-reactive protein (CRP) after 12 months.

Methods: A prospective 12-month study conducted in 1 tertiary IBD center. Baseline colonoscopy was performed. Moderate-to-severe mucosal involvement was defined as a TIGER score ≥ 100, Simple Endoscopic Score for Crohn's disease ≥ 6, Mayo Endoscopic Score > 1. FC and CRP levels were documented at each visit. Baseline TIGER, SES-CD, and MES were utilized as a predictor for FC and CRP levels after 12 months.

Results: The study population included 107 adults, 52 with CD and 55 with UC. A baseline TIGER score ≥ 100 had a sensitivity and specificity of 0.964 and 0.941, respectively, at predicting a patient having an FC level ≥ 800 μg/g and/or a CRP level ≥ 1.0 mg/dL at 12-month follow-up. A baseline TIGER score ≥ 100 was associated with increased likelihood of having FC > 100 μg/g (P < .001), and ≥ 800 μg/g (P < .001) after 12 months, despite receiving advanced therapy, after the 12-month follow-up period. Similar trends were observed with the SES-CD and MES.

Conclusions: The TIGER score is a simple endoscopic score that can be used for both CD and UC that has been shown to have both construct validity with inflammatory marker and noninferiority to the current best-referenced endoscopic scores over a 12-month follow-up period. Future studies should begin incorporating TIGER as a measure of clinical response to interventions and therapeutics.

12个月随访后,多伦多IBD全球内镜报告评分与炎症生物标志物的构建效度
背景和目的:多伦多IBD全球内镜报告(TIGER)评分是针对克罗恩病(CD)和溃疡性结肠炎(UC)患者的单一内镜评分指标。本研究的目的是评估12个月后TIGER评分与粪便钙保护蛋白(FC)和c反应蛋白(CRP)之间的直接关系。方法:在1个三级IBD中心进行为期12个月的前瞻性研究。进行基线结肠镜检查。中度至重度粘膜受累定义为TIGER评分≥100,克罗恩病简单内镜评分≥6,梅奥内镜评分bbbb1。每次就诊时记录FC和CRP水平。基线TIGER、SES-CD和MES被用作12个月后FC和CRP水平的预测因子。结果:研究人群包括107名成年人,52名患有CD, 55名患有UC。基线TIGER评分≥100在预测患者12个月随访时FC水平≥800 μg和/或CRP水平≥1.0 mg/dL时的敏感性和特异性分别为0.964和0.941。结论:TIGER评分是一种简单的内窥镜评分,可用于CD和UC,在12个月的随访期间,它已被证明具有炎症标志物的结构效度,并且与目前最佳参考的内窥镜评分相比具有非效性。未来的研究应该开始纳入TIGER作为干预和治疗的临床反应的衡量标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases 医学-胃肠肝病学
CiteScore
9.70
自引率
6.10%
发文量
462
审稿时长
1 months
期刊介绍: Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信